Replacing Mn(2+) with Co(2+) in Human Arginase I Enhances Cytotoxicity Toward L-arginine Auxotrophic Cancer Cell Lines
Overview
Biology
Authors
Affiliations
Replacing the two Mn(2+) ions normally present in human Arginase I with Co(2+) resulted in a significantly lowered K(M) value without a concomitant reduction in k(cat). In addition, the pH dependence of the reaction was shifted from a pK(a) of 8.5 to a pK(a) of 7.5. The combination of these effects led to a 10-fold increase in overall catalytic activity (k(cat)/K(M)) at pH 7.4, close to the pH of human serum. Just as important for therapeutic applications, Co(2+) substitution lead to significantly increased serum stability of the enzyme. Our data can be explained by direct coordination of l-Arg to one of the Co(2+) ions during reaction, consistent with previously reported model studies. In vitro cytotoxicity experiments verified that the Co(2+)-substituted human Arg I displays an approximately 12- to 15-fold lower IC(50) value for the killing of human hepatocellular carcinoma and melanoma cell lines and thus constitutes a promising new candidate for the treatment of l-Arg auxotrophic tumors.
Human 3D Lung Cancer Tissue Photothermal Therapy Using Zn- and Co-Doped Magnetite Nanoparticles.
de Moraes E, Siqueira Furtuoso Rodrigues M, de Menezes R, Vinicius-Araujo M, Valadares M, Bakuzis A ACS Biomater Sci Eng. 2025; 11(2):1084-1095.
PMID: 39853243 PMC: 11815621. DOI: 10.1021/acsbiomaterials.4c01901.
Yuxiao C, Jiachen W, Yanjie L, Shenglan L, Yuji W, Wenbin L Front Pharmacol. 2024; 15:1446725.
PMID: 39239650 PMC: 11375294. DOI: 10.3389/fphar.2024.1446725.
Broad-spectrum anti-cancer activity of fused human arginase variants.
Prasad Y, Anakha J, Jawalekar S, Pande A Invest New Drugs. 2024; 42(5):531-537.
PMID: 39160429 DOI: 10.1007/s10637-024-01466-8.
Russo R, Gasperini S, Bubb G, Neuman L, Sloan L, Diaz G EClinicalMedicine. 2024; 68:102405.
PMID: 38292042 PMC: 10825663. DOI: 10.1016/j.eclinm.2023.102405.
Development and characterization of fused human arginase I for cancer therapy.
Jawalekar S, Kawathe P, Sharma N, Anakha J, Tikoo K, Pande A Invest New Drugs. 2023; 41(5):652-663.
PMID: 37532976 DOI: 10.1007/s10637-023-01387-y.